NEW YORK (GenomeWeb) – Epic Sciences has raised $30 million in a Series C round of private financing that it will use to support development of its circulating tumor cell analysis platform.

The San Diego-based firm is developing a circulating rare cell analysis platform with a particular focus on developing products and services to detect CTCs in cancer. It plans to market molecular diagnostic tests that rapidly quantify proteomic and genomic changes that occur over time during the treatment of a patient's cancer from a minimally invasive liquid biopsy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.